Nufarm Limited (NUF) Earnings Call Transcript & Summary

March 24, 2020

Australian Securities Exchange AU Materials Chemicals earnings 62 min

Earnings Call Speaker Segments

Gregory Hunt

executive
#1

Thanks, Tara. Good morning, everyone, and welcome to the call. Joining me are Paul Binfield, our CFO at Nufarm, and Brent Zacharias, who heads up our Seed Technologies business. Before we get into today's presentation, I'd like to direct your attention to the disclaimer, particularly the part dealing with forward-looking statements. Now, on to the results: as you'll no doubt remember, 2019 presented us with quite a few challenges. Leaving COVID-19 aside for the moment—we'll come to that later—it's reasonable to say that difficult conditions carried over from 2019 into the first half of 2020. That said, we've moved forward on the priorities we laid out for the business last year. Safety performance has improved, our margins have been maintained, and cash flow performance is better. Additionally, we've enhanced how we get products to European customers by relocating the supply chain for the portfolio we acquired, which Nufarm now manages. Our Australian performance improvement initiative is still set to reach the projected annual run rate of AUD 10 million to AUD 15 million sooner than planned, and AUD 5 million was delivered during this first half. We've expanded that improvement effort throughout the business, and we think comparable gains are achievable in other regions. We're still on schedule for the first sales of our omega-3 oil in the second half, and we see this as a major growth driver for the business. Also, as I noted, Brent is with us today and will give an update later on. Next Wednesday the sale of our South American business closes, and that will make our balance sheet substantially stronger. Before we get to the financial results, a few words on safety. You've heard me say this before: keeping our people safe matters more than anything else, and the better performance this half came from ongoing effort and attention across our whole workforce. On the financial side, as I said, it was a very tough period, and the results show that, with revenues down roughly $100 million. Slide 5 shows a complicated outcome, shaped by the South America divestment and shifts in accounting standards. Underlying EBITDA has fallen from $121 million to $66 million, while reported NPAT came in as a $122 million loss. On the plus side for the half, operating cash flow improved, and we are making progress on bringing down net working capital. We know a substantial opportunity remains to improve further, and that will stay a continuing priority for us. Turning to what drove the result on Slide 6, it is clear that most of the first-half earnings usually originate in the Americas. What set this half apart was the effect of softer demand in North America, where sales fell by $60 million compared with last year. Nufarm wasn't alone in this, since extreme flooding pushed the U.S. crop protection industry down roughly 10% across the 2019 calendar year. The floods hit during the second half of our prior financial year, yet the fallout extended into the first half as customers worked down their stock levels and we encountered very tough competition stemming from oversupply in the market. Earnings held steady in South America, where gains from a strong market were cancelled out by tougher competition; meanwhile in Australia and Asia, earnings fell mainly because of ongoing drought conditions. In Europe, we gained share in a flat market, and the portfolios we acquired delivered higher earnings. Even so, fierce competition and escalating costs counteracted that. The Seed segment was held back by bad weather across Australia and North America, along with sales that slipped into Europe. I realize COVID-19 is what everyone is focused on right now, so I'll address it immediately. Along with seeds and fertilizers, crop protection products are classified as an essential import for the food production value chain. Growers have to be able to get their crops in the ground, and governments around the world have recognized how critical this is given today's circumstances. Demand for our products has strengthened now that seasonal conditions have improved. For the majority of our markets, we have plenty of completed product on hand to satisfy that need. Australia is tougher. We cut back on stock during the drought across the past two years, and the sudden surge in demand lined up with COVID-19-related holdups in goods arriving from China. One thing to keep in mind: fulfilling this demand requires uninterrupted operation at our plants and supply chains, both international and domestic, staying intact. Right now, all of our manufacturing sites are operating with the exception of one small factory in Malaysia. Further disruptions might emerge later on, and that is something we cannot foresee. China's situation has gotten better, so supply is coming back online in a steady way, and in the last three weeks the government lifted restrictions on domestic transportation. Trucking capacity went from roughly 20% up to now more than 50%. Regional logistics create fresh difficulties owing to border controls, particularly in Europe. Those have stayed manageable up to now. Even so, they are driving costs higher and producing certain delays in raw materials getting to our plants and in product deliveries to our customers. FX rate volatility in today's markets might affect our business as well, and Paul will cover that in greater detail later. Obviously, this is a fluid and unique situation. As of today, our business has seen no material impact. Even so, given the persistent difficulties, shifts, and unknowns, it is hard to forecast with precision what the next several months may bring. Before I hand over to Paul, a quick summary: the half has been tough on our customers, on our suppliers, and on our own staff. Despite that, our place in the market remains secure. We have kept our discipline and preserved our gross margins. Cash flow has improved, and we have launched a company-wide effort focused on generating still more cash flow and better returns. Even with the uncertainty we face, we enter the latter half of the year benefiting from improved seasonal circumstances across North America and Australia, and our balance sheet is set to become substantially stronger in the near future. I'll now hand it over to Paul, who will walk through the financial results.

Paul Binfield

executive
#2

Thanks, Greg. I'd like to build on Greg's point that this is a complex result. Our pack contains extensive detail on how AASB 16, the new leasing accounting standard, impacts the numbers, as well as on the South American discontinued operations. As you work through those figures, we're happy to walk through any questions you have on the specifics. The main message today is that while underlying earnings dropped considerably, external market conditions were largely responsible. We also acknowledge that, following the divestments of our South American businesses, there is work ahead of us to simplify the business, improve efficiencies and optimize our cost base. And as Greg mentioned, that work has already begun. Our cash flow position is better now, and we see a sizable chance to unlock additional cash from the balance sheet across the coming 18 to 24 months. Possibly the key point to convey, considering how financial markets look right now, is that once the South American businesses are divested, our balance sheet will be considerably stronger. That sale is set to close next Wednesday, and the net proceeds, roughly $1 billion, will go straight toward cutting net debt right away. If you look at the headline figures on Slide 9, it's clear that lower revenues from continuing businesses carried through into gross profit and EBITDA. Greg already mentioned this mostly happened in North America, Australia, and Asia, regions whose markets are bouncing back from tough weather. Revenue rose in Europe and South America, and gross margins will hold steady in the continuing businesses — a strong result considering how fierce competition has been in those markets. On Slide 10 we've laid out the key performance drivers for the continuing businesses in detail. Earnings from the acquired portfolios in Europe, as you can see, are up by roughly $8 million. Gross profit accounts for the biggest drop. Most of that comes from lower sales across North America, Australia, and Indonesia, though it also reflects a margin decline tied to higher manufacturing costs in Europe. Sales, distribution, and support expenses were up as well. And, as Greg noted, we have launched what we see as a significant company-wide initiative aimed at simplifying the business, optimizing our cost base, and boosting efficiency. That initiative recognizes the fact that, after divesting our South American operations, we are now a smaller company and must become a far leaner organization. Planning is still underway, but the program will span every region and every corporate support function. This builds on an initiative that began in ANZ twelve months ago. That initiative has reached an annualized run rate of $10 million in incremental earnings, and we think it provides a solid framework for the remainder of the company. At the outset, the ANZ program concentrated on back office and support functions. Now, regarding procurement, manufacturing, and sales within the program — those areas have progressed, and that is broadly how we anticipate the group-wide program to develop. Before I turn to cash flow and the balance sheet, allow me to explain the impact of AASB 16 and material items. With AASB 16 in place, group EBITDA gained $15.2 million, which reflects reversing the operating lease expense. Higher depreciation and financing costs of $16.8 million offset that gain, since the lease assets moved onto the balance sheet. Lease liabilities now appear on the balance sheet too, and from here on they will be included in net debt and in how we calculate leverage. In addition, we booked $27 million of material cost before tax during the half, and disposal costs for our South American businesses account for roughly half of it. The rest covers legal costs tied to the omega-3 canola oil patent cases plus additional restructuring costs in Australia. We expect additional significant items during the second half, and those are listed here. Turning to Slide 12. A notable highlight for the half was the gain in cash flow. Since our business follows a seasonal pattern, we always record cash outflows during the first half while inventory is bought ahead of the main selling season, and inflows during the second half as customer receivables get collected; this year we recorded a slight decrease in net working capital balances compared with the previous half. The main driver was a substantial gain in Australia, with net working capital decreasing by roughly $170 million. Inventories moved back toward typical levels, and receivables declined alongside softer sales—though the bigger factor was a reduction in days sales outstanding, or DSO. Slide 13 shows that average net working capital to sales has continued to rise, largely reflecting the effect of weaker sales during the half. We still see improving net working capital as a priority, and we believe there is room to release at least $200 million in cash from the balance sheet across the coming 18 to 24 months as we return to our medium-term target of 40%. Following the divestiture of our South American operations, we feel the longer-range objective of average net working capital to sales in the 35% to 37% range can be reached. I do need to flag, however, that during the second half we might intentionally maintain larger inventory balances as a buffer against potential COVID-19 supply chain interruptions. Even so, we are keeping our 40% target for FY '21; moving now to Slide 14, net debt and financing costs. Interest expense matched the earlier period, and it was higher foreign exchange losses that pushed up net financing costs overall. Looking to next year, our exposure to South American currencies will decline substantially. That said, we still run Nuseed operations there, and we continue to carry currency exposure in Europe, and not every bit of that can be hedged in an economic way. In these tough times there's a lot of volatility across all FX rates, and it's especially pronounced in some emerging markets, where hedging tends to be hard or uneconomic. That could mean more unforecast FX losses than expected in the second half. Net debt has risen versus a year ago, though the cause is the inclusion of lease liabilities after we adopted AASB 16. Strip that out and net debt came down slightly. In seven days, we anticipate finalizing the divestiture of our South American operations, which will significantly alter our balance sheet. After covering taxes and transaction expenses, the net proceeds—surpassing $1 billion—will be allocated to purchasing the preference securities from Sumitomo at $97.5 million and paying down approximately $925 million in net debt; going forward, our reporting of net debt and all metrics will incorporate lease liability. Therefore, to align with this change, we are shifting our leverage target range for core net debt from 1 to 1.5x to an updated range of 1.5 to 2x. I'll now hand it over to Greg to take you through the operations.

Gregory Hunt

executive
#3

Right. Thank you, Paul. Like I mentioned before, the opening six months proved extremely difficult for our regional businesses. There was hardly any let-up from the difficulties we encountered throughout 2019. Even so, as I noted previously, in spite of all that, I'm happy to report we managed to hold our standing across most of the key segments we operate in, and gross margins were sustained even with fierce competition. Our expectation is that the marketplace will stay competitive, and the group-wide performance improvement program reflects that — it's genuinely built to create a bit of a buffer against competitive pressure and unexpected developments. So moving to the regions — taking them one at a time, beginning with Europe on Slide 16; revenues grew in a market that was flat, and we picked up market share, especially in important cereal markets. That came about through better product supply and tighter supply chain control over the acquired portfolio. That said, the industry continues to feel the effects of China supply constraints and higher raw material costs, and that keeps weighing negatively on our financial results. Importantly, contribution from the acquired portfolio rose roughly $8 million versus the prior year. But that gain was offset by higher manufacturing SG&A and — or SG&A costs. During the second half, we'll be re-examining every element of how we support the business as part of the performance improvement program we've launched. Moving on to North America on Slide 17. That market took a severe hit from record flooding in 2019, with industry analysts putting the figure somewhere between 10 million and 12 million acres left unplanted, and crop protection revenues industry-wide fell by 10%. That produced an oversupplied market in the first half, with channel inventories running very high, which hurt our ability to make sales during the period as customers concentrated on de-stocking. On top of that, uncertainty over possible tariffs on imported Chinese ag chem products led customers to hold off on purchases. Revenues for the half came in $60 million below the previous year. Gross margins took a hit from tougher competition on the sales that were available, and we absorbed some cost increases stemming from the start-up of our Greenville operations. Demand has picked up considerably in March, and the challenge now is really a logistical one — getting product out to our customers before the planting window shuts. For Australia and New Zealand, the first half ranked among the toughest our industry has ever experienced, with yet another year without summer cropping in Australia, which brought revenues down $50 million compared with last year. Manufacturing under-recoveries remained a problem during the half because of lower demand stemming from the prolonged drought conditions; that carried all the way through to gross margins. Still, we managed to counter part of that hit with roughly $5 million in savings coming from the performance improvement program; we kicked off that initiative about a year ago at this point, aiming for $10 million to $15 million in yearly improvement by the close of the first half of 2021. We have now arrived at the low end of that goal, with over 70 separate projects, large and small, adding to the better performance; we also brought down net working capital in this region by roughly $170 million, and most of that gain came from cutting inventory. What we are seeing at present is a surge in demand tied to the rainfall received across most major cropping areas in late January. Our sales for February and March are ahead of the equivalent period a year ago. The difficulty in the weeks ahead, though, will be securing product and raw materials to satisfy that surge in demand; we are aware that certain products may leave us unable to fulfill all of the demand we currently have. For instance, trifluralin and herbicide are in global short supply, and that line contributed $5 million of earnings in financial year '19 which will not be delivered in financial year '20. The outlook for the second half is clearly improved thus far versus last year, though it remains subject to COVID-19 uncertainties. Naturally, we do need follow-up rain across the coming weeks to make sure winter crop planting succeeds. A few remarks about Asia. It too was hit by bad weather, with drought and elevated channel inventories in Indonesia in particular, weighing on results for the half. Sales into other countries also slipped into the second half. And we have observed higher sales in February and March. In South America, as with most of our global competitors, we recorded very strong sales growth there, especially in Brazil, where bigger soy plantings drove demand higher. Competition in this market has stayed very intense, and earnings finished slightly lower for the half because of that; our planning with Sumitomo for the handover of the business is very well advanced, and as we have said, that takes place next Wednesday; so let me now pass things to Brent for an update on Seed Technologies. Brent?

Brent Zacharias

executive
#4

Thanks, Greg. Nuseed keeps making solid strides in creating and bringing to market distinctive plant output traits that provide particular downstream advantages for customers and consumers — what we call our Value Beyond Yield strategy. During the half year, Nuseed ran into certain headwinds that affected sales and earnings within our core seeds portfolio. The main causes were the effects of drought in Australia on summer crop sales, along with endpoint royalties tied to the 2019 canola grain harvest. Even with a slower first half, demand for sorghum, canola and sunflower sales is still on track for robust global sales growth in FY '20, powered by the ongoing launch of new products across our key segments. One thing worth highlighting: we've just obtained our very first hybrid canola registration in Canada — and Canada is the biggest canola market globally. Over in Europe, demand for sunflower keeps climbing at a strong pace in 2020, although this year it skews toward second-half sales given how supply chain delivery has been timed. Our sorghum businesses across the Americas are likewise continuing to show solid growth. In Australia's main canola-growing areas, we're monitoring rainfall closely, because canola plantings for next season — typically carried out in May — will be a major swing factor affecting second-half earnings. Back in November, Nuseed acquired assets related to bringing carinata — an oilseed crop — to market as a top-tier plant-based feedstock for making biofuel. That's yet another Value Beyond Yield growth opportunity that has us very excited. Following two years of small-scale testing and development in South America, Nuseed is now working alongside growers in Argentina to significantly expand carinata acreage through a closed-loop business model. We harvested our first commercial carinata crop in Argentina during the first half period, and it has received third-party certification, delivering greenhouse gas, or GHG, reductions exceeding 100% when compared with petroleum diesel standards. Commercial talks with major offtake partners have reached an advanced stage, and we expect our first downstream sales to occur during this financial year. From our new carinata program, we anticipate a modest positive EBITDA contribution in FY '20, along with substantial expansion plans in the years ahead. Moving now to omega-3: omega-3 canola ranks among our most promising Value Beyond Yield growth platforms, and we expect first commercial sales within the current financial year. Data gathered from our wide-ranging fish feeding customer trials is being used to strengthen the value proposition of Aquaterra, and commercial preparations are advancing very well. Industry players are acknowledging that the trial results show meaningful advantages beyond sustainability, dependable supply, and convenience — with notable findings on fish health and quality as well. Because target customers have reacted favorably, we've decided to more than double the oil output we're aiming for this year, using expanded farm planting and higher-yielding varieties. The U.S. FDA regulatory submission has taken longer than we anticipated, but it continues to move forward, and we're highly confident approval will come soon. In the same way, our Canadian filings are almost through the review and approval process. Supply chain efforts are advancing too, and those will bring better efficiency while helping lower what we pay for goods as time goes on. A partnership has been formed with ADM, among the top agricultural processors globally, for crush and processing services. New seed varieties are also coming that carry improved oil and grain yield traits, and those should have a favorable effect on our supply chain costs in the next financial year. Also worth noting, Nuseed recently obtained an Excellence Through Stewardship certification, giving our partners and the industry confidence in the stewardship protocols for our traits. Our initial commercialization priority continues to be aquaculture. Beyond that, our omega-3 oil—to be sold under the Nutriterra name—is also being developed for the human nutrition sector and is currently in the last phases of a clinical trial assessment. We have started early discussions with prospective buyers in that key market. In addition, Nuseed and its collaborators concluded a U.S. Federal Court case during this period involving a portion of our patents, and the outcome affirmed the validity as well as the strength of our large intellectual property portfolio. I'll now return the floor to Greg.

Gregory Hunt

executive
#5

Thanks, Brent. We can all agree these are unusual and uncertain days, so predicting with any accuracy what lies ahead and how our business may be affected over the next few months is quite hard right now. One thing we do know is that food has to be produced, which means farmers have to plant crops. The products Nufarm makes are a vital input for a farmer's capacity to grow those crops successfully. Although the situation and the challenges change daily, demand for our products is coming in stronger. I think our teams across the globe are doing a tremendous job of actively managing how we respond to the numerous difficulties COVID-19 has created, especially our manufacturing teams, who keep showing up for work each day while most of their colleagues are working from home. These challenges are going to persist; even so, we see more opportunity to streamline our business and boost its efficiency, building a stronger foundation for better returns over the years ahead, and we will pursue those opportunities. As Brent mentioned, we expect our first sales of omega-3 canola oil before this year is out, which takes further forward what we see as a valuable platform for growth and value creation at Nufarm. And lastly, before we take questions, let me say again that we have obtained competition clearance from CADE, the competition regulator in Brazil, for the sale of our South American business. Our handover planning with Sumitomo is well advanced, and the funds from the sale will reach us next Wednesday. I'll now hand back to the operator to take some questions.

Andrew Scott

analyst
#6

Greg, you brought up better seasonal conditions in Australia, partly offset by supply chain tightness. I'm just trying to get a handle on how you view that competitively. Do you see Nufarm as better placed and potentially able to take advantage of an improved supply chain and more domestic capacity? Or do you figure everybody's on a fairly even playing field here?

Gregory Hunt

executive
#7

Well, Andrew, I think it definitely highlights the value of local manufacturing when supply is tight. I'm not saying for 1 minute that we'll fill every order for every bit of demand that exists right now. Given the drought conditions across the past two years, our inventory levels have been deliberately reduced below what we would normally hold at this time of year. Back in January, forecasts indicated no meaningful rainfall until April. Consequently, the late-January rains caught us with a supply challenge. At present, between 3,000 and 4,000 tonnes of product are in transit, with arrival anticipated within one to two weeks. Should present conditions persist and rain materialize within two to three weeks, we will be well positioned to satisfy a substantial portion of that demand. Should we receive substantial rain during the next day or two, the situation is truly hand-to-mouth — truly hand-to-mouth. Still, based on what I'm observing, my expectation is that we're typically in what's likely a better position than a number of our rivals.

Andrew Scott

analyst
#8

Got it. So in that situation, are we only talking about an improvement in volume? I'd assume that in such a tight environment — I think the term you used was hand-to-mouth — pricing moves up and you ought to see some margin expansion, provided you can actually get hold of that product.

Gregory Hunt

executive
#9

Well, at the moment we are definitely observing some upward pressure on prices. Obviously, given where the Australian dollar sits right now, our — we still need to secure those price increases regardless, since a lot of that product is bought by us in U.S. dollar terms. So our COGS is certainly going to rise; and once more, it's hard to really pin down what might happen with our costs when it comes to manufacturing operations and logistics. So I think on one hand, prices will improve, but on the other hand, there's just a bit of uncertainty about what cost may actually do over the next few weeks as well.

Andrew Scott

analyst
#10

Understood. And last, one just for Brent, on omega-3 and FDA approval. Is there any update on that?

Brent Zacharias

executive
#11

Yes. Like I said, we're fairly happy with how things keep progressing. We talk with them all the time and we back the diligence coming from FDA; and though I'm unable to reveal what those detailed conversations involve, it is progressing and they're working very actively in spite of some of the current COVID situation. So we feel quite encouraged. And as I said, I believe it's near at hand.

Grant Saligari

analyst
#12

Would you mind going into a bit more detail on a few of those product registration difficulties you mentioned for Europe? And also, what would the net impact on the business be if things went against you on that?

Paul Binfield

executive
#13

Yes, Grant, and thanks for the question. I think what we wanted to highlight is simply that, in the European context, significant regulatory pressure is just part of the life cycle management process. And looking to next year, we anticipate restrictions or possible bans on a couple of key molecules, mainly Bromoxynil and Bromethalin. That said, when some products face greater regulatory pressure, opportunities do open up elsewhere in our portfolio, so it actually gives us a chance to grow sales of other products. So at this point, the European team is essentially pointing out that, yes, there are some risks when it comes to FY '21 surrounding some fairly significant products, so it is under pressure, but they are also pointing out that opportunities exist too. But at this point, we are not calling a net decline in that situation. It is more about simply flagging that, for us, they are under pressure, and this is a continuously evolving process that we must actively manage within the context of the tough European regulatory environment.

Gregory Hunt

executive
#14

And Grant, I think I should add a bit more to that point. Paul mentioned Bromoxynil by name, and that product likely accounts for roughly $7 million in margin for our European business. It serves as a direct replacement for those SU products we picked up through the Surf portfolio. So in a lot of situations where regulatory pressure exists, and if we reached a point where we couldn't keep selling those products, we generally have alternatives available that we could offer instead.

Grant Saligari

analyst
#15

This is probably a hard question for you to answer, or to put a number on, but how much worse do you figure the environment, or the regulatory environment, has become in Europe since — you even bought the portfolios here a few years back, it's — and how tough do you figure it will get for you over the coming several years? It's a very fluid sort of situation, and it tends to be sort of moving in an adverse direction for you.

Gregory Hunt

executive
#16

I definitely think that pressure is going to continue; however, the reality is that as long as there are no alternatives, we hear a great deal about biologicals and other more natural substances, but the truth is that those products' efficacy just isn't on the same level as what we see with our products. So the pressure keeps building, but once you finally reach the question of whether those products will be banned and what farmers will do, that's a completely different situation. I'd say it's probably one of the bigger examples in Europe, I guess. We do hear a lot about bans from governments, but once the final call has to be made, it gets hard, because farmers begin asking, "What will I use instead?" And for many of these products, there aren't, I suppose, any straightforward or cost-effective substitutes. You're right that this is tough, since things are shifting. We see the pressure building, and wherever possible we've begun looking at alternatives — products of a more natural kind that could, in time, take the place of that chemistry. Still, I wouldn't call it armageddon. I don't believe it will arrive as fast as certain commentators would actually — would like us to think.

Paul Binfield

executive
#17

I think, Grant, regarding your point, if you look at that portfolio, it's clear that when we made the acquisition, we made a number of assumptions about what would happen from a regulatory standpoint. And reflecting back about 2 years later, I think our view would be that we were probably too pessimistic. Our products have probably had — have had a better regulatory outcome than we perhaps expected when the transaction took place. So it's a tough environment, but I think so far our team is doing a pretty good job when it comes to making the right calls and the right assessment.

Grant Saligari

analyst
#18

And just briefly, what's your outlook for spring planting in Europe? And to clarify the ANZ FX impact, do you believe you'll recover the full cost from an FX standpoint?

Paul Binfield

executive
#19

Well, it's still early days in terms of how things are developing. But certainly, we'd expect that since all of our competitors are largely in the same position when it comes to low channel inventory, and most of them — in fact, every one of them with USD input costs — the capacity to pass those prices along, those costs are fairly reasonable.

Gregory Hunt

executive
#20

As for conditions in Europe, I think they vary quite a bit depending on which country you focus on. Still, comparing this year with last year, things are definitely no worse than they were at this point last year. So at the moment, we aren't seeing any weather-related issues in Europe that would be material.

Richard Johnson

analyst
#21

Paul, could we return briefly to that waterfall chart you showed on Page 10? What I'm trying to do is get a clearer picture of what went on with SG&A. I'd also like to know whether you can give me a sense of how that rise was distributed across the region. For example, how much of that 23% landed in Europe?

Paul Binfield

executive
#22

Yes, of course. I'd say it's fair to characterise most of that increase as having occurred in Europe. North America makes up only a modest share, and that likely mirrors the net savings delivered by the performance improvement program in ANZ. Turning to Europe, one accounting treatment has shifted: under new legal changes in France, we can no longer give rebates to our customers, so instead we typically offer them promotional support. That creates a switch between SG&A and gross margin, but it isn't inflating the SG&A figure there, Richard. As for the rest of Europe, no particular major standout costs show up. For example, some warehousing costs are running somewhat higher since we're holding more inventory on the ground there. We're seeing certain expense pressures emerge, particularly in the area of promotional spending. There are numerous minor areas where costs have risen. The origin of the cost reduction effort—or the performance enhancement initiative we're currently implementing across the remainder of the organization—stems from our belief that we can achieve significantly better results in getting those expenses to deliver more value for us. That's among the reasons we're examining this situation and stating that we aren't pleased with the rise in SG&A costs, and we're exploring what steps we can take to bring that under improved management. And it has worked remarkably well within the ANZ business. All we're doing is applying that identical template across the remainder of the region.

Richard Johnson

analyst
#23

Right, understood. That's useful. So looking back, do you see anything in that figure that could perhaps have been avoidable?

Paul Binfield

executive
#24

Hindsight's a great thing, I suppose. When you consider the costs we've put into the business for some of the new portfolios coming in, honestly, a portion of those costs probably landed before the revenue did. So looking back, yes, I'd want to see maybe a more considered build when it comes to those costs, Richard, but apart from that, no significant growth.

Richard Johnson

analyst
#25

Understood; that's excellent, Paul. Very useful. And just to be clear, are you saying that the — what you'll be doing going forward, the quantum of savings would be comparable to what you've — what you plan to achieve in Australia?

Paul Binfield

executive
#26

I believe it will differ from region to region, and that means we must take a careful look at the opportunities within each region and how we can best take advantage of them. And once more, to be clear, this won't be only SG&A; we'll be examining logistics, supply chain, manufacturing. We'll be taking a careful look at the business just as we did in the ANZ region too.

Gregory Hunt

executive
#27

Richard, on the subject of Europe in particular, our sense is that we've resolved quite a few of the problems there during the past 12 months. Most of our attention has gone toward product supply and getting the new ERP system validated; therefore, over the coming 12 months our attention will move toward boosting our efficiency so we can offset part of the cost increases we've encountered during this last period.

Richard Johnson

analyst
#28

Understood. And then, Brent, on omega-3 specifically — apologies if you already covered this and I missed it — but could you walk us through the logic and maybe attach some figures to the fact that you're doubling your volume production target in FY '21? I'm trying to grasp what that really translates to.

Brent Zacharias

executive
#29

Absolutely. Thanks, Richard. Yeah, I suppose what we're aiming to convey is that we're raising our acres at the same time as bringing in new genetics that deliver higher green and oil yields, and likely also shifting into some zones with higher production. So our target overall — I know in the past we've discussed acres more — but the overall target is to more than double how much oil volume we actually deliver to the marketplace. So looking back at our history, we moved from 3,000 acres to 15,000 to 35,000 last year. And instead of simply quoting an acre figure, we feel it's more meaningful to state that, starting from a 35,000 acre base last year, we now intend to more than double the oil volume we plan to bring to market in this next year.

Richard Johnson

analyst
#30

All right, so I just want to make sure — that applies to sales or delivery within the same year, correct, rather than the year after.

Brent Zacharias

executive
#31

No, my apologies. Right, we're going to put more acres into planting during 2020, and those sales will hit our FY '21 period.

James Ferrier

analyst
#32

My first question concerns gross margins. In the presentation deck, I believe you mentioned that the result delivered a margin that was flat at 27% compared with PCP. Could you clarify whether that figure is normalized, meaning it excludes the European rebate issue and excludes any movement related to AASB 16?

Paul Binfield

executive
#33

James, that is on a like-for-like basis.

James Ferrier

analyst
#34

Yes. All right. So with that in mind, Paul, you've got a situation where, definitely before, at least in the near past, raw material costs have been higher and Nufarm hasn't been able to raise prices, broadly speaking, enough to offset that; so as we look toward the second half, is it a fair expectation that gross margins would come in around the same level as PCP?

Paul Binfield

executive
#35

That seems like a fairly reasonable assumption to me, James. Take Europe as an illustration: our first half has been very strong for the Surf and Century portfolio, and those products usually carry a higher margin than our foundational product, so there's a mix benefit there. But I'd point out as well that, owing to some of the supply problems out of China that hurt us during '19 and simply the lack of product availability, we ended up with somewhat higher COGS. Some of those elevated COGS are still flowing through in '20, and part of that will remain true in the second half too; so I'd say the outlook we have is that we're actually working through some of that more expensive inventory right now. We still expect some of it to persist into the second half, but our outlook is likely more optimistic than at this point last year, when I think we felt we were in the thick of it until the troubles from those constrained supply issues came to an end.

James Ferrier

analyst
#36

Yes, all right. That's a positive sign. Regarding FX, since business activity is heavily weighted toward the second half and the A dollar has weakened sharply, there must be a sizable expected gain from translation. Could you remind us of the average translation rates in FY '19 for the main currencies, perhaps the U.S. dollar and the euro?

Paul Binfield

executive
#37

Yes. I believe there's actually a slide near the back, James, I think it's Slide 30. So basically, what we're saying is that for the half, it probably wasn't too different for the full year: USD was 68.5, euro was 62 and pound was 54; so looking at rates today, you're talking about a fairly substantial shift from the rates that prevailed last year.

James Ferrier

analyst
#38

Yes. All right. And then I believe you mentioned that if we go further down the P&L, there could be some headwinds related to hedging and FX losses, given the volatility, but what you're referring to there is the translation benefit that would flow through EBITDA.

Paul Binfield

executive
#39

Yes. So basically, we see tailwinds when it comes to operating performance, exactly as you said. But we are worried; we have some exposures in certain emerging markets, for instance, Romania, Poland, Hungary, where currency volatility is quite consistent. Hedging is difficult, probably uneconomic to hedge, and there is the potential, depending on how currency tracks over the next 4 or 5 months, that we might take some higher FX losses during that period. But it really is something to watch out for. But yes, we'll be exiting LATAM obviously in a couple of weeks, but we still do have some smaller but still significant exposures. And in the current environment, that can be painful.

James Ferrier

analyst
#40

All right, that makes sense. When the LATAM divestment was announced, the document mentioned a possible risk of dis-synergies, perhaps involving procurement costs as the group's scale got smaller. Has anything further developed on that front that you could comment on?

Gregory Hunt

executive
#41

James, the agreement includes that Nufarm will keep managing supply for the next 2 years, negotiating and continuing to negotiate for products supplied into Latin America. So during that time we don't expect any significant impact. If, over that period, Sumitomo decides that going forward they want to handle procurement themselves, then potentially there is some — I guess if we lost those volumes, our negotiating ability might have some impact. And as I said, whatever Sumitomo does after that 2-year period is entirely their call. And our argument would then be that by combining our buying power, we actually achieve a better result, which is, if you recall why, really 3, 4 years ago, we centralized that and placed a team in China so that we could gain the benefit of having countries negotiate on their own. I mean everyone is trying to solve for their operations. Nobody is trying to solve for a one Nufarm. So that's the logic. We think it's compelling. And we'll be trying to convince our friends that they will be better off with Nufarm doing that. When it comes to products we develop in our portfolio, the agreement we have is that those products will be offered to Sumitomo; and if, for whatever reason, they decide they don't want to distribute those products in Latin America, then we have the right to offer them to other companies. So from that point of view, we see little downside.

James Ferrier

analyst
#42

All right, that makes sense. And to wrap up a few things for clarity, regarding the trifluralin matter in Australia. From what I understand, especially in WA, that business usually gets done during the first half. So with the $5 million impact you mentioned, I'd figure part of that has already been felt in the first half.

Paul Binfield

executive
#43

Most of it tends to land in our second half, James, so that's an H2...

Gregory Hunt

executive
#44

Those would be the sales we typically generate around this point in the year. Perhaps slightly sooner, but definitely following the first half.

James Ferrier

analyst
#45

All right, got it. And then, finally, when you mention oil production for omega-3 doubling in FY '21, does that alter the economics enough that you'd raise your earnings guidance for omega-3 for that year?

Brent Zacharias

executive
#46

Right now, we're still giving the same guidance of EBITDA positive in FY '21.

Alex Karpos

analyst
#47

Are you able to hear me?

Gregory Hunt

executive
#48

Yes, Alex, I can hear you loud and clear.

Alex Karpos

analyst
#49

Great. I'd like to zero in on North America briefly. I understand the context you gave about the floods, and obviously that carries over into inventories. At what point in that de-stocking process are we? And if the end hasn't arrived yet, how much longer do you expect it to take?

Gregory Hunt

executive
#50

In my discussions with customers in North America, they've cut stock considerably over the last 6 months, but what we've observed is an unwillingness to buy at the levels we'd typically have seen in December and January. Much of that has spilled over into February and March. And demand is coming through very strongly. If we look at what we delivered last year, the real question is how much of that $60 million we believe we can recover in the second half. That's the challenge I mentioned. It essentially turns into a logistics exercise. Since we're getting the demand, we're currently holding $400 million of inventory in North America, and we have additional products and additional raw materials on the water, subject to restrictions that could arise around moving products from our factories to and across state borders, and those are matters we handle every day. With some tailwinds, I believe we can recover a fairly large portion of the shortfall we've seen in the half. Demand is very strong.

Alex Karpos

analyst
#51

Understood. And would it be reasonable to say that the majority of your rivals are up against the same kind of supply chain constraints, meaning that if all of you are dealing with a similarly tighter inventory picture, then pricing ought to be fairly supportive throughout this region?

Gregory Hunt

executive
#52

Well, Alex, that's what I'd assume. My attention has really been on our own business, so I haven't spent too much time looking at our competitors. Still, I'd certainly expect that a lot of them are encountering precisely the same problems that we are.

Alex Karpos

analyst
#53

Understood. And just one last thing. I might have gotten this wrong when you were all discussing seeds, but did I understand it correctly when you said that at this point the lawsuits were mostly, sort of, resolved, with the litigation still ongoing?

Paul Binfield

executive
#54

Regarding...

Alex Karpos

analyst
#55

The patent infringement cases.

Paul Binfield

executive
#56

Sure. Okay. Brent?

Brent Zacharias

executive
#57

Alright, I’ll take that one. Yes, what I had said was that during the first half, we wrapped up a proceeding in a U.S. Federal Court. That proceeding rested on a subset of our patents, and it reaffirmed infringement as well as validity for those patents. So in that specific case, some post-trial motions remain, and appeals could follow, but that is the current status of that case.

John Purtell

analyst
#58

I've got a few quick questions if that's alright. Greg, on the level of competition in the markets — you mentioned before that North America and Europe are staying very competitive, and I'd guess that's just what weak demand does. But do you think that will settle down, or has it already settled based on what you're seeing right now? Clearly, a fair amount of product should move in the second half, but I'd imagine everyone is fighting for that too.

Gregory Hunt

executive
#59

Yes, John. My view is that things will stay fairly competitive while consolidation works itself out, but I do believe that in certain pockets, as we've already talked about, there will be chances to raise prices and lift margins. And where product is in short supply, that is already happening. My caution, the thing I'd flag, is that we're beginning to see supply chain costs that are really hard to get a handle on right now; but there's sort of anecdotal stuff every day where we have people who can't show up or aren't showing up for shifts, logistics costs around getting access to trucks, trucks trying to cross borders and backed up, having to wait 10 or 12 hours for clearance. So I mean all of these things are going to add some cost to our business that is just very hard to quantify. But certainly, when it comes to demand, when it comes to sales and price increases, there's no question we are seeing that.

John Purtell

analyst
#60

And just 2 other ones; regarding the products you mentioned that are facing more regulatory pressure, is that kind of tied to environmental issues? Or what is actually going on that's driving it?

Paul Binfield

executive
#61

This is mainly in Europe, John; and it simply comes down to the fact that the regulator there is adopting a stricter stance, whether on environmental issues or health issues; and it simply is, I suppose, a continuation of the path we've witnessed in Europe, probably across the last 5 to 7 years. So there isn't any real stepping up of pressure, but certainly, it remains a constant focus for the regulator. It is the toughest market without a doubt. And as I say, that gives us hurdles and challenges but gives us opportunities as well.

Gregory Hunt

executive
#62

I think it likely receives more attention these days, John. I mean, that's fair to say in the cases that have sort of brought all of these matters into view. Paul is correct. If you consider the difficulties we've faced across Europe over the past 4 or 5 years, difficulties always arise regarding products entering and leaving the market. Certainly, the — when we reflect on the Century and Surf so-called acquisitions, there are items within them that have delivered considerable upside for us, upside we could not have foreseen. A number of these products currently facing regulatory pressure, products we obtained within that portfolio, would serve as substitutes for several of those products that are under regulatory pressure.

John Purtell

analyst
#63

And lastly, back on the FX topic — I just want to understand how revenue and costs really move through your business. Clearly, a number of your products are sold across different regions. So I can see the translation gains in Aussie dollars, but how much cost pressure in local currency will you be up against here in Australia and in other markets where U.S. dollar products are involved, and how well can you recover that?

Paul Binfield

executive
#64

How well you recover, John, tends to hinge on whether your manufacturing footprint and what you're doing set you apart from your peers. Turning to Australia, I'd say it's reasonable to note that nearly every competitor of ours will bring goods in using U.S. dollars or euros. As a result, they'll run into comparable foreign-exchange challenges. As for the U.S., there's really not much of a problem there, since once again imports will largely be in USD and sales will largely be in USD. And once more, the picture in Europe matters much less, in the sense that what you have there is imports in USD and euros alongside sales in euros. What worries me more regarding FX, John, is the gains and losses that come from net working capital positions in certain emerging markets — there we could take a painful hit and likely book a somewhat one-time loss. That's my real concern.

Operator

operator
#65

Thanks. There are no more questions. So I think that brings today's conference call to a close. Thanks to everyone for joining. You can disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.